BridgeBio Pharma Inc BBIO

NAS: BBIO | ISIN: US10806X1028   14/11/2024
24,11 USD (-2,74%)
(-2,74%)   14/11/2024

30 januari 2024 · Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics · Persbericht

25 juli 2022 · BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A · Persbericht

25 januari 2022 · Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments · Persbericht

19 november 2021 · BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types · Persbericht

4 november 2021 · BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update · Persbericht

3 november 2021 · BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease · Persbericht

29 oktober 2021 · BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers · Persbericht

25 oktober 2021 · BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors · Persbericht

12 oktober 2021 · BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers · Persbericht

7 oktober 2021 · BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models · Persbericht

6 oktober 2021 · BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 · Persbericht

1 oktober 2021 · BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants · Persbericht

15 september 2021 · BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) · Persbericht

8 september 2021 · BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

18 augustus 2021 · BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors · Persbericht

5 augustus 2021 · BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update · Persbericht

5 augustus 2021 · BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 juli 2021 · BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations · Persbericht

12 juli 2021 · BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 juli 2021 · BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions · Persbericht

Mijn selecties